Sydney: Monday 2 February 2026:

Professor Gilles Guillemin, Bionyeri co-founder and CEO, has achieved an H-index score of 100 GoogleScholar for research across a range of health -related conditions.

Find out more here: Gilles J. Guillemin, AM, GAICD‬ – Google Scholar‬

This achievement is significant for Prof Gilles and his multiple collaborators throughout the world for their research on the kynurenine pathway, neurodegeneration, cancers, chronic and infectious diseases.

“I am incredibly proud and grateful to be continuing this work at Bionyeri with a focus on pain and cancer and the development a new generation of natural products to help improve patient outcomes,” Professor Guillemin said.

Pain and cancer are growing health issues on a global basis. The mortality rate for cancer is high with one in five people diagnosed with the disease each year and 20.5 million new cases recorded  year on year, according to the World Health Organisation. 

Further, with 20 per cent of the world’s population living with pain from a range of health conditions, the burden on the health system is significant.

For pain, direct healthcare costs in Australia alone exceed $12.2 billion per annum.  

There is no effective natural treatment for pain relief making people rely on chemical drugs such as opioids, steroids, paracetamol or non-steroidal anti-inflammatory drugs (NSAID). These have well documented side effects and in the case of opioids, high levels of addiction. 

Professor Guillemin added: “We are on a mission to solve some of these health problems through development the next generation of natural products.”

About Bionyeri Pty Ltd: www.bionyeri.com 

Bionyeri is a Research and Development Biotech company based in Sydney Australia .Our focus is on using bioactive and plant extracts to develop a new generation of natural products with enhanced delivery techniques to help relieve symptoms of pain in a range of health conditions.

Our vision is to become a market leader in the development of natural products for pain and cancer relief which are backed by scientific evidence and experiments conducted from our PC2 accredited facility.